United States Patent 9,155,699: Scope, Claim Architecture, and US Landscape

US Patent 9,155,699 covers a specific dry powder pulmonary composition built around three fixed elements: high-dose levodopa, sodium chloride, and (optionally or mandatorily depending on claim format) phospholipid excipients. The claims are drafted to lock down (i) composition ratios, (ii) powder physical properties tied to inhalation performance (tap density and aerodynamic size), and (iii) a narrow embodiment using DPPC and an explicit levodopa:DPPC:NaCl ratio of ~90:8:2.

This patent’s enforceable perimeter in the US is therefore defined less by “levodopa for inhalation” broadly and more by combination + particle engineering that produces powder characteristics associated with pulmonary delivery.

What does claim 1 actually cover? (core independent claim scope)

Claim 1: composition claim anchored on three ingredients and “dry powder particles”

Claim 1 reads:

“A composition of dry powder particles formulated for pulmonary delivery comprising about 75 weight percent levodopa or more and sodium chloride.”

Key claim takeaways for scope

Excipients are not limited beyond sodium chloride in claim 1. The claim requires at least levodopa (>= ~75 wt%) and NaCl, but does not exclude additional excipients unless dependent claims add restrictions.
“About 75 wt% or more” is a moving boundary. In enforcement, “about” invites interpretation. Practically, the claim targets high levodopa loading rather than low-percentage formulations.
Pulmonary delivery is a formulation purpose tied to “dry powder particles.” This generally strengthens argument that the formulation is intended for inhalation but still leaves technical room around what makes particles “formulated for pulmonary delivery” (e.g., size/density).

Claim style implications

Claim 1 is open (not “consisting of”). This is important for landscape mapping because a challenger can potentially design around by changing excipients unless dependent claims force “consisting of.”

How do dependent claims narrow the perimeter? (feature stacking)

Dependent claims add specific particle and excipient constraints. The independent scope becomes significantly narrower as limitations accumulate.

Phospholipid add-on: claim 2

Claim 2: “particles further comprise a phospholipid or a combination of phospholipids.”

This makes phospholipid a required element in claim 2 and downstream dependents.

DPPC specific: claim 14

Claim 14: phospholipid is dipalmitoyl phosphatidylcholine (DPPC).

This is a strong narrowing point. Any product substituting other phospholipids (e.g., DSPC, hydrogenated lecithin, etc.) avoids the DPPC-specific claim 14, while potentially still falling under claim 2 if the phospholipid category is met.

What particle engineering parameters are claimed? (tap density and aerodynamic size)

A large fraction of the claim set is dedicated to physical properties that correlate with respirable fraction and device performance.

Tap density constraints

Claim 3: tap density about 0.4 g/cm³ or less
Claim 8: tap density about 0.3 g/cm³ or less
Claim 9: tap density about 0.2 g/cm³ or less
Claim 10: tap density about 0.1 g/cm³ or less

Interpretive impact

These claims create a ladder of narrower sub-classes.
A formulation with tap density above 0.4 g/cm³ avoids claim 3 and all tap-density dependents.

Volume median geometric diameter (VMGD) constraint

Claim 4: volume median geometric diameter about 5 micrometers or more.

Aerodynamic diameter windows

Claim 5 provides the broadest aerodynamic window; claims 6 and 7 carve it into sub-ranges:

Claim 5: aerodynamic diameter from about 1 μm to about 5 μm
Claim 6: aerodynamic diameter from about 1 μm to about 3 μm
Claim 7: aerodynamic diameter from about 3 μm to about 5 μm

Practical reading

Any accused formulation must place its respirable particles (as measured under the patent’s methods) into one of these windows, at least to reach the relevant claim.

What sodium chloride loading is claimed? (percentage cutoffs)

Dependent claims tightly control NaCl content, which is an unusual choice given many inhaled formulations avoid high salt loads.

Claim 11: NaCl about 10 wt% or less
Claim 12: NaCl about 5 wt% or less
Claim 13: NaCl about 2 wt% or less

Enforcement leverage

These cutoffs offer multiple design-around routes: exceeding a NaCl threshold may avoid certain dependent claims (11-13) but not necessarily claim 1, which only requires “sodium chloride” plus levodopa >= about 75 wt%.

What are the “consisting of” claims (hard boundaries)?

Two claims switch from open to closed language, which materially narrows what can be accused.

Claim 15: three-component “consisting of” embodiment

“A composition of dry powder particles consisting of about 75% or more levodopa, sodium chloride and dipalmitoylphosphatidylcholine.”

Scope effect

“Consisting of” generally excludes other components not recited (subject to purity/trace levels and interpretation). This makes claim 15 a high-friction target for any formulation that uses additional excipients beyond levodopa, NaCl, and DPPC.

Claim 16: explicit ratio “consisting of”

“consisting of levodopa, sodium chloride and dipalmitoylphosphatidylcholine, wherein the ratio of levodopa:dipalmitoylphosphatidylcholine:sodium chloride is about 90:8:2.”

Scope effect

This is the narrowest commercial target. It requires not only the three ingredients but also a specific ratio (again with “about” wiggle room).

Claim-by-claim mapping: what must an accused product have to infringe?

Below is a structured view of the incremental requirements beyond claim 1.

Claim	Added required limitations beyond claim 1	Category
2	At least one phospholipid	Ingredient
3	Tap density ≤ 0.4 g/cm³ (about)	Powder physical
4	VMGD ≥ 5 μm (about)	Particle size
5	Aerodynamic diameter 1-5 μm (about)	Respirability window
6	Aerodynamic diameter 1-3 μm (about)	Respirability window subset
7	Aerodynamic diameter 3-5 μm (about)	Respirability window subset
8	Tap density ≤ 0.3 g/cm³ (about)	Powder physical
9	Tap density ≤ 0.2 g/cm³ (about)	Powder physical
10	Tap density ≤ 0.1 g/cm³ (about)	Powder physical
11	NaCl ≤ 10 wt% (about)	Ingredient ratio limit
12	NaCl ≤ 5 wt% (about)	Ingredient ratio limit
13	NaCl ≤ 2 wt% (about)	Ingredient ratio limit
14	Phospholipid is DPPC	Ingredient specificity
15	“Consisting of” levodopa + NaCl + DPPC; levodopa ≥ ~75 wt%	Closed formulation
16	“Consisting of” with ratio ~90:8:2 (levodopa:DPPC:NaCl)	Closed formulation + ratio

What is the likely claim “center of mass”? (most commercial products will need to hit multiple constraints)

For a typical high-loading inhaled levodopa dry powder, three axes will dominate whether a product is within reach:

Ingredient stack: levodopa at ~75 wt% or more + sodium chloride
Phospholipid choice: DPPC if aiming at claims 14-16
Powder performance: aerodynamic size in 1-5 μm range plus low tap density targets (as low as ≤0.1 g/cm³ in claim 10)

The closed claims (15 and 16) tighten design freedom. Open claims (1-13, 2-14) allow additional excipients as long as they do not negate the claimed “comprising” structure and the measured physical properties.

US patent landscape: how to read 9,155,699 in the broader field

Where this patent sits in an inhaled levodopa portfolio

Even without reproducing other patents’ full claim texts here, 9,155,699 is best treated as a formulation-and-process-adjacent physical-property patent rather than a “drug use” patent. Its claim set targets:

composition formulation (ingredient presence and high levodopa loading)
salt inclusion (NaCl as structural/processing contributor)
phospholipid stabilization/surfactant role (phospholipid category and DPPC specific)
particle engineering (tap density, VMGD, aerodynamic diameter ranges)
closed embodiment (consisting of; explicit ratio)

This pattern typically appears in portfolios that aim to protect a particular platform for pulmonary delivery rather than a single device.

Competitor design-around levers

Given the claim structure, the most direct ways to reduce infringement exposure are:

Change the tap density target above 0.4 g/cm³ (avoid claims 3 and all tap-density dependents).
Shift aerodynamic diameter out of 1-5 μm (or concentrate outside 1-5 μm).
Modify NaCl level such that it exceeds the relevant “about 10/5/2 wt%” limits if the product is trying to avoid dependent claims 11-13.
Swap DPPC for other phospholipids to avoid claim 14 and closed claims that require DPPC.
Add additional excipients to avoid “consisting of” coverage in claims 15 and 16.
Change the exact levodopa:DPPC:NaCl ratio away from ~90:8:2 to avoid claim 16 even if the three components remain.

Enforceability map: which claims drive litigation risk

Commercial risk concentrates on claims that are both specific and likely met by engineered inhalation powders.

High-risk claims

Claim 1: levodopa >= ~75 wt% + NaCl + dry powder for pulmonary delivery
Claim 2 + claim 5: phospholipid present and aerodynamic diameter 1-5 μm
Claim 14 + claim 5: DPPC used with aerodynamic window
Claim 15 and 16: “consisting of” plus either DPPC requirement and/or explicit ratio

Lower-probability claims

Tap density ladder claims depend on how the product measures tap density and whether the powder meets the low density thresholds.
VMGD claim 4 can be missed depending on milling and size distribution management.

Business implications for R&D and investment diligence

If you are building within the same technical space

The patent’s internal consistency suggests the protected platform uses:

high levodopa loading
a salt component at relatively low percentages in the dependent claims
a phospholipid (often DPPC)
powder properties tuned to yield aerodynamic diameters in 1-5 μm
low tap density, likely to improve dispersibility

A product that hits the same combination is exposed, even if it differs in small ways unless those differences sit outside the claimed parameters or avoid “consisting of.”

If you are evaluating acquisition or licensing

Diligence should prioritize:

excipient roster (are there any extra ingredients that would help avoid “consisting of”?)
measured tap density (does it clear the 0.4/0.3/0.2/0.1 g/cm³ thresholds?)
measured aerodynamic diameter distributions under the patent’s characterization method
confirm whether the formulation uses DPPC specifically
NaCl wt% relative to the 10/5/2 thresholds
whether the product lands near the explicit ratio window for claim 16

Key Takeaways

US 9,155,699 protects a dry powder pulmonary levodopa + sodium chloride composition with high levodopa loading (about 75 wt% or more).
The claim set is structured as a stack of measurable powder attributes: tap density (down to ≤0.1 g/cm³), VMGD (≥ about 5 μm), and aerodynamic diameter (about 1-5 μm, split into 1-3 μm and 3-5 μm).
Phospholipids are required in dependent claims, with DPPC specifically required in claim 14.
Claims 15 and 16 use “consisting of”, materially narrowing permissible formulations to levodopa + NaCl + DPPC and, for claim 16, a ~90:8:2 ratio.
Design-around is most achievable by shifting at least one of: tap density, aerodynamic diameter, NaCl wt%, phospholipid identity (DPPC vs non-DPPC), or by adding excipients to avoid “consisting of” limitations.

FAQs

1. Which ingredient is mandatory in the broadest independent claim?

Levodopa at about 75 wt% or more and sodium chloride are required in claim 1, for a dry powder formulated for pulmonary delivery.

2. Does the patent require DPPC?

DPPC is required only in claim 14 and in the closed formulations of claims 15 and 16. Claims 1-13 can require phospholipid generally via claim 2 without requiring DPPC.

3. What aerodynamic size ranges are protected?

The patent claims aerodynamic diameter about 1-5 μm (claim 5), with sub-ranges 1-3 μm (claim 6) and 3-5 μm (claim 7).

4. What tap density thresholds are claimed?

Tap density is claimed at ≤0.4 g/cm³ (claim 3) and further narrowed in steps to ≤0.3, ≤0.2, and ≤0.1 g/cm³ (claims 8-10).

5. Which claims are most limiting from a formulation-permissibility standpoint?

Claims 15 and 16 use “consisting of,” so any added non-recited ingredients are a key risk driver, and claim 16 also requires an explicit ~90:8:2 levodopa:DPPC:NaCl ratio.

References

United States Patent No. 9,155,699. Claims provided in user prompt.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003218307	⤷ Start Trial
Canada	2478980	⤷ Start Trial
Cyprus	1118517	⤷ Start Trial
Denmark	1531798	⤷ Start Trial
Denmark	2630954	⤷ Start Trial
European Patent Office	1531798	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,155,699

Summary for Patent: 9,155,699